NRX PHARMACEUTICALS INC (NRXP)
$0.73
+0.03
(+4.29%)▲
Insights on NRX PHARMACEUTICALS INC
Vs SGEN
In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 57.5%
Performance
- $0.69$0.74$0.73
5.75%
Downside
Day's Volatility :7.03%
Upside
1.35%
- $0.49$1.54$0.73
32.33%
Downside
52 Weeks Volatility :67.92%
Upside
52.6%
Returns
| Period | NRX PHARMACEUTICALS INC | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.19% | 0.7% | -7.0% |
6 Months | -47.1% | -7.9% | -6.5% |
1 Year | -13.47% | -2.0% | -6.8% |
3 Years | -96.99% | 25.4% | 24.7% |
Highlights
Market Capitalization | 49.2M |
Book Value | $0.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.57 |
Wall Street Target Price | 4.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -72.78% |
Return On Equity TTM | -237.83% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -38.1M |
Diluted Eps TTM | -0.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.38 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 539.73%
Technicals Summary
Sell
Neutral
Buy
NRX PHARMACEUTICALS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 NRX PHARMACEUTICALS INC | 13.2% | -47.1% | -13.47% | -96.99% | -96.99% |
 Moderna, Inc. | -2.19% | -29.52% | -8.32% | 114.67% | 590.97% |
 Regeneron Pharmaceuticals, Inc. | -8.43% | -4.6% | 15.93% | 18.38% | 134.28% |
 Seagen, Inc. | -2.63% | 59.03% | 43.99% | 21.05% | 216.49% |
 Vertex Pharmaceuticals Incorporated | -6.48% | 0.7% | 19.84% | 13.84% | 116.25% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
NRX PHARMACEUTICALS INC | NA | NA | NA | -0.56 | -2.38 | -0.73 | 0.0 | 0.0 |
Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
NRX PHARMACEUTICALS INC | Buy | $49.2M | -96.99% | NA | 0.0% |
Moderna, Inc. | Buy | $49.1B | 590.97% | 11.46 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 134.28% | 19.91 | 33.81% |
Seagen, Inc. | Hold | $36.7B | 216.49% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 116.25% | 26.18 | 35.4% |
Institutional Holdings
Vanguard Group Inc
2.07%Geode Capital Management, LLC
0.53%BlackRock Inc
0.52%Bridgeway Capital Management, LLC
0.32%State Street Corporation
0.16%Northern Trust Corp
0.10%
Corporate Announcements
NRX PHARMACEUTICALS INC Earnings
NRX PHARMACEUTICALS INC’s price-to-earnings ratio stands at None
Read More
Company Information
NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.
Organization | NRX PHARMACEUTICALS INC |
Employees | 0 |
CEO | Dr. Jonathan C. Javitt M.D., M.P.H. |
Industry | Healthcare |
Discover More
Janus International Group, Inc.
$8.94
+1.25%
JPMORGAN BETABUILDERS US SC
$53.55
+1.09%
BJ's Restaurants
$30.22
+1.48%
American Axle & Manufacturing Holdings I
$6.85
+1.48%
Two Harbors Investment Corp.
$12.86
+3.38%
Telecom Argentina S.A.
$5.10
+5.15%
NuShares ESG International Developed Markets Equity ETF
$28.37
+1.65%
GAMIDA CELL LTD
$2.16
+2.86%
Patrick Industries Inc.
$67.99
+3.75%